Trading volume for Spark Therap Cmn was 962K on Tuesday. Shares saw a steep increase in trading volume of 88.92% over the normal average daily volume.
Short traders are feeling a little more bullish on shares of the company lately if you look at the decrease in short interest. The company recorded a fall in short interest of -1.93% as of October 13, 2017 from the last reporting period. Short interest decreased 43,514 over that timeframe. With short interest at 2,211,661 and short average daily volume at 571,098, the short-interest ratio is 4.0 and the percentage of shorted shares is 0.06% as of October 13.
Spark Therap Cmn (NASDAQ:ONCE) has been the object of insider selling activity recently. Chief Business Officer Daniel Faga disclosed the sale of 7,500 shares of (ONCE). The shares were sold on October 24th for a price of $82.48. Faga now owns $0 of the stock according to the SEC filing. Katherine A. High, See Remarks reported the sale of 5,000 shares. The shares were purchased at an average price of $85.81. The See Remarks now owns $18,020,100 of the stock per the Form 4 SEC filing.
Chief Business Officer Daniel Faga let go of 1,500 shares at an average price of $85.00 on Tue the 19th. That brings Faga’s holdings to $0 per an SEC filing yesterday.
A few notable investment firms have updated their holdings. Baker Bros. Advisors Lp added to its holdings by buying 65,789 shares an increase of 5.0%. Baker Bros. Advisors Lp claims 1,384,130 shares worth $123,409,000. The total value of its holdings increased 56.7%. As of quarter end Ubs Asset Management Americas Inc had disposed of 3,110 shares trimming its holdings by 88.9%. The value of the investment in ONCE decreased from $208,971,000 to $34,594,000 decreasing 83.4% for the reporting period.
AXA cut its investment by selling 19,198 shares a decrease of 15.5% from 06/30/2017 to 09/30/2017. AXA controls 104,528 shares valued at $9,320,000. The value of the position overall is up by 26.1%. Alliancebernstein L.P. expanded its position by buying 6,310 shares an increase of 10.4% as of 09/30/2017. Alliancebernstein L.P. now controls 66,810 shares with a value of $5,957,000. The value of the position overall is up by 64.8%.
Equity analyst Royal Bank Of Canada raised the price target on November 8 changing the price objective from $98.00 to $100.00 and issued a “Outperform” recommendation. October 25 investment analysts at Royal Bank Of Canada kept a “Buy” rating on the company.
On October 16, 2017 SunTrust Banks released research on ONCE with a rating of “Buy” and projecting a price target of $101.00. Barclays PLC raised the price target on October 13 changing the forecast from $104.00 to $107.00 with a rating of “Overweight”.
October 13 investment analysts at Chardan Capital kept the stock rating at “Buy” projecting a price of $100.00. On October 13 BMO Capital Markets made no change to the stock rating of “Outperform” with a current price target of $101.00.
The company is so far trading down from yesterday’s close of 68.25. The most current P/E ratio is N/A and the market value is 2.52B. As of the latest earnings report the EPS was $-7.20 with 37.01M shares outstanding.
Spark Therapeutics, Inc. (Spark), launched on March 13, 2013, is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. The Business’s product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD) caused by non sex-linked, or autosomal recessive, biallelic mutations in the RPE65 gene. The Company has received orphan product designation for voretigene neparvovec for the treatment of RPE65-mediated IRD in both the United States and the European Union..